# Thomas Gibbs

> Thomas Gibbs is a Series B investor at Debiopharm Innovation Fund backing Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Debiopharm Innovation Fund](https://shizune.co/investors/profile/debiopharm-innovation-fund)
- Total investments: 3
- Last investment: Dec 2012
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/tom-gibbs-21a7b13/
- Website: https://www.debiopharm.com/debiopharm-innovation-fund/management/

Thomas Gibbs is a Series B investor at Debiopharm Innovation Fund focused on Biotechnology and Medical Device. Thomas Gibbs received his bachelor's degree science in applied biology from the University of Wales Institute of Science and Technology, and earned his doctor's degree in philosophy in microbial genetics at the University of Warwick. He has spent more than two decades in the commercialization of life science technologies, split equallybetween the pharmaceutical industry and scientific tool developers. He has been responsible for a wide range of activities including quality assurance, operations, late-stage product development and marketing, and increasingly business development. He has broad experience in both startups such as Cytion, Covalys, and Med Discovery and more established companies such as Delta Biotechnology, Molecular Devices, and Debiopharm in Europe and the United States of America. He joined Debiopharm International in 2012.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 33% |
| Medical Device | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Series C | 1 | 33% |
| Series D | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biocartis Group NV | Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $37.8M | Series D | Dec 12, 2012 |  |
| Biocartis Group NV | Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $77.9M | Series C | Nov 17, 2011 |  |
| Biocartis Group NV | Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexeddetection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland. | $32.9M | Series B | Apr 08, 2010 |  |

3 of 3 investments shown.

## Co-investors
- [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) — VC Fund, 3 deals together
- [Advent Venture Partners](https://shizune.co/investors/profile/advent-venture-partners) — VC Fund, 1 deal together
- [Aescap Venture](https://shizune.co/investors/profile/aescap-venture) — VC Fund, 1 deal together
- [KBC](https://shizune.co/investors/profile/kbc) — VC Fund, 1 deal together
- [Korys](https://shizune.co/investors/profile/korys) — VC Fund, 1 deal together
- [New Rhein](https://shizune.co/investors/profile/new-rhein-healthcare) — VC Fund, 1 deal together

## About Debiopharm Innovation Fund

VC Fund · Lausanne, Switzerland

Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.

5 contacts available at Debiopharm Innovation Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Cedric Odje | Senior Investment Associate | https://shizune.co/investors/profile/cedric-odje |
| Nicole Wilson | Senior Administrative Assistant | https://shizune.co/investors/profile/nicole-wilson-10b6 |
| Tanja Dowe | Chief Executive Officer | https://shizune.co/investors/profile/tanja-dowe |
| Thomas Gibbs | Director | https://shizune.co/investors/profile/tom-gibbs |
| Vincent Lepreux | Investment Principal | https://shizune.co/investors/profile/vincent-lepreux |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Thomas Gibbs invest in?

Thomas Gibbs invests primarily in Biotechnology, Medical Device and Health Diagnostics startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Thomas Gibbs last invest?

The most recent investment recorded for Thomas Gibbs closed in Dec 2012. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co